Abstract: Objective This study aimed to investigate endoscopic varies ligation (EVL) and tissue glue plus lauromacrogol sandwich therapy in patients with hepatitis B-induced liver cirrhosis (LC) and esophagogastric variceal bleeding (EGVB). Methods 75 patients with hepatitis B-induced LC and complicated EGVB were emergently admitted to our hospital between September 2020 and September 2025, and were assigned to underwent EVL and endoscopic lauromacrogol sclerotherapy in 35 cases in control, or to underwent EVL and endoscopic tissue glue and lauromacrogol sandwich therapy in another 40 cases in observation group. Endoscopy was conducted one month later. Results Two(5.0%)in the observation and seven patients (20.0%)in the control group died, with successfulhemostasis of 95.0% in the former, much higher than 80.0%(P＜0.05) in the latter; there was no significant difference as respect to incidences of re-bleeding in the two groups (7.9% vs. 21.4%, P>0.05); after treatment, total serum bilirubin, albumin and hemoglobin levels in survivals in the observation group were(15.6±1.6)μmol/L, (33.5±2.9)g/L and (86.5±8.1)g/L,all not significantly different as compared to [(15.3±1.9)μmol/L, (33.8±3.1)g/L and (87.3±7.9)g/L, P＞0.05] in those in the control group. Conclusion EVL and tissue glue plus lauromacrogol sandwich therapy in patients with hepatitis B-induced LC and complicated EGVB is clinically efficacious, with satisfactory hemostasis and less re-bleeding.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Endoscopic varies ligation, Tissue glue, Lauromacrogol, Therapy